Isolation and Preliminary Characterisation of Active B-Chain of Recombinant Tissue-Type Plasminogen Activator

Summary

Purified 2-chain recombinant tissue-type plasminogen activator (t-PA) was reduced under mild conditions - 10 mM dithiothreitol/ 5° C/1.5 h - and the two chains were separated by chromatography on lysine Sepharose. The t-PA B chain was fully active as determined by its activity towards the chromogenic substrate S-2288 (H-D-ile-pro-arg p-nitroanilide). Analysis by sodium dodecyl sulphate polyacrylamide gel electrophoresis under reducing or non-reducing conditions revealed a single polypeptide at Mr = 35,000 or 29,000 respectively. In addition, under non-reducing conditions a fibrinolytic band at apparent Mr = 29,000 was present after fibrin zymography. The N-terminal sequence was confirmed as ile-lys-gly. The t-PA B chain had a specific amidolytic activity, using S-2288, of 170,000 to 210,000 SU/mg protein. (This compares to a specific activity of the native 2-chain t-PA of 170,000 SU/mg). It resembles urokinase-type plasminogen activator in its inability to be stimulated by fibrin and its dose response on human fibrin plates. However, t-PA B-chain was stimulated to almost the same extent as t-PA by poly-D-lysine. The isoelectric points, at pH 5.6 and 5.7, fall outside the range generally quoted for t-PA preparations (pH 7.8-8.8).

Key words

Tissue-type plasminogen activator - Fibrinolysis - Urokinase-type plasminogen activator

• References

• 1 Werf FVan de, Ludbrook PA, Bergman SR, Tieffenbrun AJ, Fox KA A, De Geest H, Verstraete M, Collen D, Sobel BE. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med 1984; 310: 609-613
• 2 Van de Werf F, Bergmann SR, Fox KA A, De Geest H, Hoyng CF, Sobel BE, Collen D. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 1984; 69: 605-610
• 3 Rijken DC, Collen D. Purification and characterisation of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
• 4 Collen D, Rijken DC, Van Damme J, Billiau A. Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluid and its conditioning for use in vivo. Thromb Haemostas 1982; 48: 294-296
• 5 Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983; 301: 214-221
• 6 Browne MJ, Dodd I, Carey JE, Chapman CG, Robinson JH. Increased yield of human tissue-type plasminogen activator obtained by means of recombinant DNA technology. Thromb Haemostas 1985; 54: 422-424
• 7 Rijken DC. Isolation and functional properties of the light chain of tissue-type plasminogen activator. Haemostasis 1984; 14: 14
• 8 Wallen P, Pohl G, Bergsdorf N, Ranby M, Ny T, Jörnvall H. Purification and characterisation of a melanoma cell plasminogen activator. Eur J Biochem 1983; 132: 681-686
• 9 Porath J, Carlsson J, Olsson I, Belfrage G. Metal chelate affinity chromatography, a new approach to protein fractionation. Nature 1975; 258: 598-599
• 10 Browne MJ, Tyrrell AW R, Chapman CG, Carey JE, Glover DM, Grosveld FG, Dodd I, Robinson JH. Isolation of a human tissue-type plasminogen activator genomic DNA clone and its expression in mouse L cells. Gene 1985; 33: 279-284
• 11 Laemmli UK. Cleavage of structural proteins during the assembly of the head of Bacteriophage T4. Nature 1970; 227: 680-685
• 12 Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-234
• 13 Ouchterlony O. Diffusion-in-gel methods for immunological analysis. Prog Allergy 1958; 5: 1-78
• 14 Robinson J. Induction of plasminogen activator in a human diploid fibroblast cell line (MRC-5) by conditions which cause induction of interferon: the role of calcium ions. Thrombos Res 1984; 33: 155-162
• 15 Fears R, Hibbs MJ, Smith RA G. Kinetic studies on the interaction of streptokinase and other plasminogen activators with plasminogen and fibrin. Biochem J 1985; 229: 555-558
• 16 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
• 17 Allen RA, Pepper DS. Isolation and properties of human vascular plasminogen activator. Thromb Haemostas 1981; 45: 43-50
• 18 Allen RA. An enhancing effect of poly-lysine on the activation of plasminogen. Thromb Haemostas 1982; 47: 41-45
• 19 Petersen GC, Brender J, Svenson E. Zymogen-activation kinetics. Biochem J 1985; 225: 149-159
• 20 Sueishi K, Nanno S, Okamura T, Inoue S, Tanaka K. Purification and characterisation of human kidney plasminogen activator dissimilar to urokinase. Biochim Biophys Acta 1982; 717: 327-336
• 21 Binder BR, Spragg J, Austen KF. Purification and characterisation of human vascular plasminogen activator derived from blood vessel perfusates. J Biol Chem 1979; 254: 1998-2003